Protalix BioTherapeutics (PLX) Operating Expenses (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Operating Expenses of $1.3 million for Q1 2026, down 79.15% year-over-year from $6.0 million in Q1 2025, and down 52.28% quarter-over-quarter from $2.6 million in Q4 2025.
Protalix BioTherapeutics (PLX) Operating Expenses (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 79.15% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $16.4 million (down 28.44% YoY), while the FY2025 annual figure was $21.0 million, up 18.38% from the prior year.
- Operating Expenses for Q1 2026 stood at $1.3 million, down from $2.6 million in the prior quarter.
- The five-year high for Operating Expenses was $11.9 million in Q1 2022, with the low at $1.3 million in Q1 2026.
- The 5-year median for Operating Expenses is $7.4 million (2024), against an average of $7.0 million.
- The sharpest annual moves came in 2025 and 2026: Operating Expenses jumped 38.57% in 2025, then slumped 79.15% in 2026.
- Protalix BioTherapeutics' Operating Expenses stood at $8.7 million in 2022, then declined by 16.87% to $7.2 million in 2023, then tumbled by 73.8% to $1.9 million in 2024, then jumped by 38.57% to $2.6 million in 2025, then sank by 52.28% to $1.3 million in 2026.
- Business Quant data shows PLX's Operating Expenses at $1.3 million in Q1 2026, $2.6 million in Q4 2025, and $7.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 5.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.84 Mn |
| Mar 31, 2026 | 1.26 Mn |
| Dec 31, 2025 | 2.63 Mn |
| Sep 30, 2025 | 7.79 Mn |
| Jun 30, 2025 | 4.69 Mn |
| Mar 31, 2025 | 6.02 Mn |
| Dec 31, 2024 | 1.90 Mn |
| Sep 30, 2024 | 7.36 Mn |
| Jun 30, 2024 | 7.60 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 7.25 Mn |
| Sep 30, 2023 | 7.34 Mn |
| Jun 30, 2023 | 8.51 Mn |
| Mar 31, 2023 | 8.96 Mn |
| Dec 31, 2022 | 8.72 Mn |
| Sep 30, 2022 | 10.23 Mn |
| Jun 30, 2022 | 10.19 Mn |
| Mar 31, 2022 | 11.92 Mn |
| Dec 31, 2021 | 11.11 Mn |
| Sep 30, 2021 | 10.24 Mn |